Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.

Journal Article (Journal Article)

The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognised that "triple therapy" with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis and major bleeding. This document describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton-pump inhibitors and the use and duration of triple therapy following stent placement based upon the risk assessment.

Full Text

Duke Authors

Cited Authors

  • Faxon, DP; Eikelboom, JW; Berger, PB; Holmes, DR; Bhatt, DL; Moliterno, DJ; Becker, RC; Angiolillo, DJ

Published Date

  • October 2011

Published In

  • Thromb Haemost

Volume / Issue

  • 106 / 4

Start / End Page

  • 572 - 584

PubMed ID

  • 21785808

Electronic International Standard Serial Number (EISSN)

  • 2567-689X

Digital Object Identifier (DOI)

  • 10.1160/TH11-04-0262


  • eng

Conference Location

  • Germany